Company Filing History:
Years Active: 2018
Title: Shinobu Mori: Innovator in Pharmaceutical Composition
Introduction
Shinobu Mori is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the prevention and treatment of urinary incontinence. His innovative approach sets him apart from conventional drugs.
Latest Patents
Mori holds a patent for a pharmaceutical composition aimed at preventing and treating urinary incontinence. The invention provides a novel therapeutic agent that includes 1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methyl}amino)pyrimidin-5-yl]-1H-pyrrole-3-carboxamide or a salt thereof as an active ingredient. This composition addresses the need for more effective treatment options in this area.
Career Highlights
Throughout his career, Shinobu Mori has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Astellas Pharma GmbH and Cytokinetics, Inc. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.
Collaborations
Mori has collaborated with esteemed colleagues, including Yusuke Kajihara and Hiroko Inamura. These partnerships have fostered innovation and have been instrumental in the development of his patented pharmaceutical composition.
Conclusion
Shinobu Mori's contributions to the pharmaceutical field, particularly through his patent for urinary incontinence treatment, highlight his role as an innovator. His collaborations and career achievements further underscore his impact on the industry.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.